Cover	12 Months Ended
Cover	Dec. 31, 2024
Document Information [Line Items]
Document Type	DEF 14A
Amendment Flag	false
Entity Information [Line Items]
Entity Registrant Name	Arcus Biosciences, Inc.
Entity Central Index Key	0001724521

Pay vs Performance Disclosure - USD ($)

12 Months Ended

Dec. 31, 2024

Dec. 31, 2023

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Pay vs Performance Disclosure

Pay vs Performance Disclosure, Table

The following table discloses additional compensation information of (i) our Chief Executive Officer and (ii) all other named executive officers (the "Other NEOs"), including “compensation actually paid” during the specified years alongside total shareholder return ("TSR") and net income metrics:


					Value of initial fixed $100 investment based on:
Year(1)	Summary compensation table total for CEO ($)	Compensation actually paid to CEO(2)(3) ($)	Average summary compensation table total for Other NEOs ($)	Average Compensation actually paid to Other NEOs(2)(4) ($)	Total shareholder return(5) ($)	Peer group total shareholder return(5) ($)	Net income(6) ($ millions)
2024	7,279,504	4,803,366	2,793,357	1,696,346	147.43	95.43	(283)
2023	10,120,945	7,480,720	4,193,925	2,953,574	194.36	94.37	(307)
2022	9,048,432	(2,065,105)	4,191,618	(2,394,074)	204.75	87.61	(267)
2021	9,483,339	14,577,932	5,939,512	7,091,681	400.69	117.83	53
2020	5,685,664	12,015,409	5,363,707	10,455,559	257.03	148.03	(123)

Named Executive Officers, Footnote

Our Chief Executive Officer for each of the years presented was Dr. Rosen. Our Other NEOs for 2024, 2023 and 2022 were Robert C. Goeltz, Juan Jaen, Jennifer Jarrett and Dimitry Nuyten. Our Other NEOs for 2021 were Robert C. Goeltz, Juan Jaen, Jennifer Jarrett, Carolyn Tang and William Grossman. Our Other NEOs for 2020 were Jennifer Jarrett and William Grossman.

Peer Group Issuers, Footnote

TSR figures assume an initial investment in our common stock of $100 on December 31, 2019. The peer group referenced for purpose of the TSR comparison is the group of companies included in the S&P Biotechnology Index, which is the industry peer group used for purposes of Item 201(e) of Regulation S-K. The separate peer group used by the Compensation Committee for purposes of determining compensation paid to our executive officers is described on page 26.

PEO Total Compensation Amount

$ 7,279,504

$ 10,120,945

$ 9,048,432

$ 9,483,339

$ 5,685,664

PEO Actually Paid Compensation Amount

$ 4,803,366

7,480,720

(2,065,105)

14,577,932

12,015,409

Adjustment To PEO Compensation, Footnote

The adjustments made to the summary compensation table total for Dr. Rosen for each year presented above to determine compensation actually paid to Dr. Rosen in such year are shown in the tables below:


	2024	2023	2022	2021	2020
Summary compensation table total	7,279,504	10,120,945	9,048,432	9,483,339	5,685,664
Less, value of stock & option awards	(5,924,960)	(8,909,833)	(8,292,320)	(8,548,858)	(5,356,475)
Plus year-end value of awards granted in fiscal year that are unvested and outstanding	4,156,034	5,634,249	3,788,462	7,142,260	7,893,097
Plus change in fair value of prior year awards that are outstanding and unvested	(1,390,550)	(573,908)	(5,490,389)	3,923,736	1,828,423
Plus FMV as of the vesting date of awards granted this year and that vested this year	1,363,210	1,648,267	1,608,814	1,783,385	1,108,163
Plus change as of the vesting date in fair value (from prior year-end) of prior year awards that vested this year	(679,872)	(439,000)	(2,728,104)	794,070	856,537
Total adjustments	(2,476,138)	(2,640,225)	(11,113,537)	5,094,593	6,329,745
Compensation actually paid to CEO	4,803,366	7,480,720	(2,065,105)	14,577,932	12,015,409

Non-PEO NEO Average Total Compensation Amount

$ 2,793,357

4,193,925

4,191,618

5,939,512

5,363,707

Non-PEO NEO Average Compensation Actually Paid Amount

$ 1,696,346

2,953,574

(2,394,074)

7,091,681

10,455,559

Adjustment to Non-PEO NEO Compensation Footnote

The adjustments made to the average summary compensation table total for Other NEOs for each year presented above to determine average compensation actually paid to Other NEOs in such year are shown in the tables below:


	2024	2023	2022	2021	2020
Summary compensation table total	2,793,357	4,193,925	4,191,618	5,939,512	5,363,707
Less, value of stock & option awards	(1,918,678)	(3,364,997)	(3,444,851)	(5,298,516)	(4,864,788)
Plus year-end value of awards granted in fiscal year that are unvested and outstanding	1,345,900	2,127,890	1,848,729	3,797,282	6,969,591
Plus change in fair value of prior year awards that are outstanding and unvested	(591,055)	(367,886)	(4,050,985)	2,678,504	1,656,950
Plus FMV as of the vesting date of awards granted this year and that vested this year	441,522	622,491	528,662	1,094,353	509,856
Plus change as of the vesting date in fair value (from prior year-end) of prior year awards that vested this year	(374,700)	(257,849)	(1,467,247)	678,367	820,243
Less, prior year fair value of prior year awards that failed to vest this year	—	—	—	(1,827,217)	—
Plus adjustments for stock modification	—	—	—	29,396	—
Total adjustments	(1,097,011)	(1,240,351)	(6,585,692)	1,152,169	5,091,852
Compensation actually paid to Other NEOs	1,696,346	2,953,574	(2,394,074)	7,091,681	10,455,559

Compensation Actually Paid vs. Total Shareholder Return

The graphs below show the relationship between (i) the compensation actually paid to both our Chief Executive Officer and the Other NEOs for the years set forth in the Pay versus Performance Table and (ii) the net income/loss and total shareholder return for the corresponding years:

Compensation Actually Paid vs. Net Income

Total Shareholder Return Vs Peer Group

TSR figures assume an initial investment in our common stock of $100 on December 31, 2019.

Total Shareholder Return Amount

$ 147.43

194.36

204.75

400.69

257.03

Peer Group Total Shareholder Return Amount

95.43

94.37

87.61

117.83

148.03

Net Income (Loss)

$ (283,000,000)

$ (307,000,000)

$ (267,000,000)

53,000,000

(123,000,000)

PEO Name

Dr. Rosen

Additional 402(v) Disclosure

Fair value or change in fair value, as applicable, of equity awards in the "compensation actually paid" columns was determined by reference to (i) for RSU awards, closing price on applicable year-end dates or, in the case of vesting dates, the actual vesting price and (ii) for stock options, the fair value estimated using a binomial lattice model as of the applicable year-end or vesting date(s). Key inputs included the contractual terms of each agreement such as vesting date, maturity date, and exercise price, while additional key inputs included the closing stock price, volatility, dividend rates, risk free rates, and an early-exercise factor which were all determined as of the revaluation date.eflects after-tax net income attributable to stockholders prepared in accordance with GAAP for each of the years shown.

PEO

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

$ (2,476,138)

$ (2,640,225)

$ (11,113,537)

5,094,593

6,329,745

PEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(5,924,960)

(8,909,833)

(8,292,320)

(8,548,858)

(5,356,475)

PEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

4,156,034

5,634,249

3,788,462

7,142,260

7,893,097

PEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(1,390,550)

(573,908)

(5,490,389)

3,923,736

1,828,423

PEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

1,363,210

1,648,267

1,608,814

1,783,385

1,108,163

PEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(679,872)

(439,000)

(2,728,104)

794,070

856,537

Non-PEO NEO

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(1,097,011)

(1,240,351)

(6,585,692)

1,152,169

5,091,852

Non-PEO NEO | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(1,918,678)

(3,364,997)

(3,444,851)

(5,298,516)

(4,864,788)

Non-PEO NEO | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

1,345,900

2,127,890

1,848,729

3,797,282

6,969,591

Non-PEO NEO | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(591,055)

(367,886)

(4,050,985)

2,678,504

1,656,950

Non-PEO NEO | Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

441,522

622,491

528,662

1,094,353

509,856

Non-PEO NEO | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(374,700)

(257,849)

(1,467,247)

678,367

820,243

Non-PEO NEO | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

(1,827,217)

Non-PEO NEO | Plus Adj for Stock Modification [Member]

Pay vs Performance Disclosure

Adjustment to Compensation, Amount

$ 0

$ 29,396

$ 0

Award Timing Disclosure	12 Months Ended
Award Timing Disclosure	Dec. 31, 2024
Award Timing Disclosures [Line Items]
Award Timing MNPI Disclosure	Our Compensation Committee has adopted an Equity Administration Policy which implements a framework for a consistent process for granting, pricing and administering equity-based awards. The policy establishes the terms of all equity-based awards issued by the Company to officers, employees and consultants under our equity plans. The policy establishes the terms for such grants including the grant effective date, pricing and vesting. For example, all equity awards will have a grant effective date of the next 8th or the 23rd of a calendar month (whichever occurs first) following approval by the Compensation Committee. If such day is not a trading day, the effective date of such grant will be the next trading day thereafter. During 2024, we did not grant stock options, stock appreciation rights, or similar option‐like instruments to our named executive officers during the four business days prior to or the one business day following the filing of our periodic reports or the filing or furnishing of a Form 8-K that discloses material nonpublic information. Our Compensation Committee does not take material nonpublic information into account when determining the timing or terms of awards, and we have not timed the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation.
Award Timing Method	For example, all equity awards will have a grant effective date of the next 8th or the 23rd of a calendar month (whichever occurs first) following approval by the Compensation Committee. If such day is not a trading day, the effective date of such grant will be the next trading day thereafter.
Award Timing Predetermined	true
Award Timing MNPI Considered	true
Award Timing, How MNPI Considered	Our Compensation Committee does not take material nonpublic information into account when determining the timing or terms of awards, and we have not timed the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation.
MNPI Disclosure Timed for Compensation Value	false

Insider Trading Policies and Procedures	12 Months Ended
Insider Trading Policies and Procedures	Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted	true